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Summary: The intestinal clearance of ocrantiproteinase, monomeric IgA and IgG, and the daily fecal output
of polymeric IgA and IgM were investigated in patients with inflammatory bowel diseases (inactive and active
Crohn's disease, ulcerative colitis) and in a control group. The intestinal clearance of arantiproteinase was
significantly increased in all patients with inflammatory bowel diseases (p < 0.01), irrespective of the grade
of the disease. In contrast, increases in intestinal clearances of monomeric IgA and IgG were more closely
related to the severity of the intestinal lesions. The associate determination of these three quantities should
therefore be of interest for monitoring the degree of intestinal bowel inflammation. Faecal output of polymeric
IgA was significantly increased in active intestinal disease (p < 0.01), whereas faecal IgM levels were not.
The determination of the faecal output of polymeric IgA should contribute to the assessment of the activity
of inflammatory bowel diseases, and may provide insight into the activation of the mucosal immune system.
Introduction
The intestinal clearance of oti-antiproteinase ("ocran-
titrypsin") has been suggested as a marker of intestinal
protein loss during inflammatory bowel diseases such
as Crohrfs disease and ulcerative colitis (1, 2). How-
ever, the use of this quantity in the assessment of
inflammatory bowel disease activity remains contro-
versial (3, 4). Owing to the absence of a specific
mucosal transfer system, the monomeric IgA of in-
testinal secretions appears to be derived mainly from
passive transport of plasma monomeric IgA (5, 6).
These monomeric IgA are relatively resistant to in-
testinal proteases and are found in the faeces in their
native form or as fragments often bound to aranti-
proteinase or pigments (7 — 9). Moreover, their intes-
tinal clearance appears to be markedly increased dur-
ing diarrhoea (10). Jonard et al. have demonstrated
that IgG, present in the intestinal secretions of healthy
subjects, are serum-derived (5). We therefore evalu-
ated the value of determining monomeric IgA and
IgG intestinal clearances, together with that of ai-
antiproteinase, for the purpose of exploring the degree
of intestinal protein loss syndrome, which in turn is
related to mucosal permeability. Moreover, it is well
established that immunological events occur inside
the inflamed lamina propria, causing changes in the
relative proportions of Ig-producing cells (IgA, IgG
and IgM) in the diseased mucosa, as well as in in vitro
Ig secretion by mononuclear cells of the lamina propria
(11 — 16). In healthy subjects, intestinal humoral im-
munity is mainly mediated by polymeric IgA, with 70
to 95 percent of secretory IgA partially protected from"
proteolysis by the extra-epithelial moiety of the poly-
Ig receptor i.e. the secretory component (17 — 19).
IgM, monomeric IgA and IgG play a less important
role in this setting (5, 17, 18). The determination of
the faecal output of polymeric IgA and IgM may
provide a means of evaluating, in vivo, the repercus-
sions of inflammatory bowel disease on local humoral
immunity, which in turn represents an evaluation of
the activity of the disease.
The present work was therefore undertaken to deter-
mine the intestinal clearance of o^-antiproteinase,
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monomeric IgA and IgG, as well as faecal output of
polymeric IgA and IgM in an homogeneous popula-
tion of patients with active and inactive Crohn's dis-
ease and ulcerative colitis, in comparison with normal
controls. The diagnostic and prognostic values of
these functions in monitoring intestinal protein loss,
and characterizing the pathophysiology and immu-




Four groups of patients were studied. The control group con-
sisted of 20 healthy adults (10 females, median age 48 years,
range 19 — 75; 10 males, median age 37 years, range 20 — 62)
with no intestinal disturbances and normal faecal constituent
values. Of 57 selected patients with inflammatory bowel disease,
25 had various degrees and (or) localisations of Crohrfs disease,
the diagnosis dating from two to twenty-three years. They were
separated into two groups on the basis of the Crohn's disease
activity index (20). The first consisted of 10 patients (3 females,
median age 22 years, range 19—42; 7 males, median age 29
years, range 22 — 66) with inactive Crohn's disease (activity
index < 150). Four of these patients had ileitis, 3 had ileocolitis,
and 2 had pure colitis disease. The second group consisted of
15 patients (9 females, median age 33 years, range 21—67; 6
males, median age 41 years, range 21 — 59) with active Crohn's
disease (activity index > 150). Of these patients, 4 had ileitis,
5 had ileocolitis, and 6 had pure colitis disease. The remaining
32 patients (20 females, median age 39 years, range 12 — 72; 12
males, median age 44 years, range 17 — 53) had ulcerative colitis,
diagnosed six months to twenty-one years previously.
Preparat ion of samples
Twenty-four-hour stools were collected on three consecutive
days and weighed. Occult blood was sought using routine
guaiac tests (Hemocult II®, Smithkline diagnostics, USA and
Hemofec®, Boehringer Mannheim, Germany). After mixing the
3-days sample from each subject with sodium azide (1 g/1 final
concentration) and di-isopropylfluorophosphate (Sigma, Saint
Louis MI, USA) at a final concentration of 1 mmol/1, five
grams of the homogenized material was removed and vigor-
ously stirred for l h with 10 ml of 0.15 mol/1 NaCl at + 4 °C.
After centrifugation (10000g, 10 min), the supernatant was
immediately frozen to — 20 °C. All assays were performed using
these three-fold-diluted stool samples. Five ml of blood was
drawn from each subject on the last day of stool collection and
the serum was stored at — 20 °C until use.
oci -Ant iprote inase determinat ion
Serum and faecal arantiproteinase were measured by single
radial immunodiffusion. Nor-Partigen® plates (Behring-diag-
nostic, Rueil-Malmaison, France) were used for undiluted
serum while LC-Partigen® plates (Behring) were used for 1 : 9
and 1 : 30 diluted faecal samples to avoid zone phenomena.
Measurement of total IgA, monomeric IgA and po-
lymeric IgA
Total IgA and monomeric IgA were measured in serum and
faeces by means of a modified electroimmunodiffusion method
according to Meillet et al. (10). The electroimmunodiffusion
was run for 18 h at + 4 °C (2 V cm"1) in an agarose-polyacryl-
amide gel, in the presence of a gel barrier which blocked the
migration of proteins with relative molecular masses MT
> 200 000. Two series of deposits, with 5 μΐ of samples or
standards [purified monomeric IgA, 14.3 g/1, prepared accord-
ing to the method of Fine (21)], were made on both sides of
the blocking gel. Samples placed above the blocking gel gave
the total IgA by comparison with the standard. A correction
factor of 1.8 was applied to take into account the precipitation
peak height difference between monomeric IgA and polymeric
IgA for the same concentration. The monomeric IgA concen-
tration was determined, without correction, by placing the
samples and the standards under the blocking gel and compar-
ing the results with the standard curve. The difference between
the two values represented polymeric IgA.
Measurement of IgG and IgM
IgG and IgM were measured in an electroimmunodiffusion
assay using 1% lEF-agarose (Isogel®, Pharmacia, Uppsala,
Sweden) containing 0.5 percent antiserum (anti-γ and anti-μ,
respectively; Dakopatts, Denmark). Serum samples diluted
1 :20 and undiluted faecal extracts were measured against
serum standards (Protein standard serum LC-A and LC-V,
Behring). The assays were run for 18 h at + 4 °C at a potential
gradient of 2 V cm"1 in a migration buffer composed of 0.03
mol/1, pH 8.4 Tris-barbital.
Presentation of results
Daily faecal outputs of IgM and polymeric IgA were expressed
as mg/24 h. Intestinal clearances of ocrantiproteinase, mono-
meric IgA and IgG were calculated according to the usual
formula and expressed as ml/24 h (2).
Statistical analysis
The specificity and the sensitivity of the biological markers were
calculated. The upper limit of normal for faecal constituent
values was defined as the mean of control values plus two
standard deviations. Since the data did not conform to a Gauss-
ian distribution, the results are given as median and range, and
were compared using the non-parametric Mann & Whitney "U"
test. Correlations were studied by means of Spearman's corre-
lation test.
Results
The median fresh weight of faeces was significantly
increased (p < 0.01) in patients with inflammatory
bowel disease: 120g/24h (range 65 — 255) for con-
trols, 197g/24h (range 47-379) for patients with
inactive Crohn's disease, 306 g/24 h (range 119-699)
for patients with active Crohn's disease and 210 g/
24 h (range 59 — 966) for patients with ulcerative col-
itis. Faecal occult blood was detected in none of the
patients with quiescent Crohrfs disease, in 5 patients
with active Crohn's disease and in 17 patients with
ulcerative colitis. Intestinal clearances of arantipro-
teinase, monomeric IgA and IgG in patients and
normal controls are illustrated in figure 1. Relation-
ships between Crohn's disease activity index and these
clearances are presented in figure 2. a^Antiproteinase
clearance was significantly raised (p < 0.01) in all the
patients with inflammatory bowel disease, compared
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Fig. 1. Intestinal clearance of ocrantiproteinase, monomeric
IgA and IgG (ml/24 h) in normal controls, patients with
inactive and active Crohn's disease, and patients with
ulcerative colitis. The medians are indicated by a hori-
zontal line.
with the normal controls. The median values obtained
in each group were 10.5 ml/24 h (range 0.4 — 16) for
controls, 51.6 ml/24 h (range 25.3 -122.2) for patients
with inactive Crohn's disease, 91.2 ml/24 h (range 12 —
265.6) for patients with active Crohn's disease and
59.8 ml/24 h (range 0 - 258.8) for those with ulcerative
colitis. Using an upper limit of normal of 20 ml/24 h,
this value increased with perfect specificity (100%)
and good sensitivity (inactive Crohn's disease: 90%;
active Crohn's disease: 93%; ulcerative colitis: 81%).
However, the increase was not statistically correlated
with the grade of the disease. The median intestinal
clearance of monomeric IgA was 0.8 ml/24 h (range
0-7.6) for controls, 1.8 ml/24 h (range 0-45.7) for
patients with inactive Crohrfs disease, 23.3 ml/24 h
(range 2.3 — 68.9) for patients with active Crohrfs
disease and 6.9 ml/24 h (range 0 — 70.9) for those with
ulcerative colitis. The upper limit of normal was fixed
at 7 ml/24 h. Under these conditions, intestinal clear-
ance of monomeric IgA increased with good specific-
ity (95%), similar to that of arantiproteinase, whereas
its sensitivity appeared to be related to the disease
activity: 73% of patients with active Crohn's disease
and 53% of those with ulcerative colitis had an ele-
vated intestinal clearance of monomeric IgA against
only 40% of those with inactive Crohrfs disease. Sta-
tistical analysis showed a significant increase
(p < 0.01) in intestinal clearance of monomeric IgA
only in patients with active Crohn's disease and ul-
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Fig. 2. Relationship between Crohn's disease activity index and
(a) intestinal clearance of ai-antiproteinase (r = 0.435, ρ < 0.1);
(b) intestinal clearance of monomeric IgA (r = 0.539, ρ < 0.02);
(c) intestinal clearance of IgG (r = 0.620, ρ < 0.01) and
(d) daily faecal excretion of polymeric IgA (r = 0.605, ρ < 0.01).
Eur. J. Clin. Chem. Clin. Biochem. / Vol. 30, 1992 / No. 4
200 Kapel et al.: Faecal arantiproteinase and immunoglobulins in inflammatory bowel diseases
related to the grade of the disease in Crohn's disease.
No correlation between arantiproteinase clearance
and monomeric IgA clearance was found, except for
patients with active Crohn's disease (p < 0.05). The
median intestinal clearance of IgG in the control
group was 0.13 ml/24 h (range 0.03-0.52). This value
was significantly increased in patients with inactive
Crohn's disease (p < 0.05) (median value 0.26 ml/
24 h, range 0.07 — 1.16), in patients with active
Crohn's disease (p < 0.01) (median value 0.7 ml/24 h,
range 0.15 — 8.2) and in those with ulcerative colitis
(p < 0.01) (median value 1.0 ml/24 h, range 0.02-
17.1). The upper limit of normal of this value was
fixed at 0.5 ml/24 h. It increased with good specificity
(92%) and sensitivity, similar to that of monomeric
IgA intestinal clearance: 30% of patients with inactive
Crohn's disease, 73% of those with active Crohn's
disease and 56% of those with ulcerative colitis
showed elevated intestinal clearance of IgG. Regard-
less of the type and grade of inflammatory bowel
disease, no correlation was found between the intes-
tinal clearances of arantiproteinase and IgG. In con-
trast, intestinal clearances of monomeric IgA and IgG
correlated well in patients with active Crohrfs disease
(p < 0.05) or ulcerative colitis (p < 0.01).
The faecal output of IgM was not affected by inflam-
matory bowel disease: the median values obtained in
each group were 1.4 mg/24h (range 0.5 — 2.6) for
controls, 1.9 mg/24 h (range 1 — 5.7) for patients with
inactive Crohn's disease, 3.5 mg/24h (range 1.Ο-
Ι 8.0) for patients with active Crohn's disease and 3.0
mg/24h (range 1.0 — 36.2) for those with ulcerative
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Fig. 3. Daily faecal excretion of polymeric IgA (mg/24 h) in
normal controls, patients with inactive and active
Crohn's disease, and patients with ulcerative colitis. The
medians are indicated by a horizontal line.
in each group was 2.0 mg/24 h (range 0.8 — 81.8) for
controls, 10.5 mg/24 h (range 2.5-293.5) for patients
with inactive Crohn's disease, 141.3 mg/24 h (range
8.9—443.9) for patients with active Crohn's disease
and 135.5 mg/24 h (range 4.5-686.8) for those with
ulcerative colitis (fig. 3). Statistical analysis showed a
significant increase in the faecal output of polymeric
IgA in patients with quiescent Crohn's disease
(p < 0.05), active Crohrfs disease (p < 0.01) and ul-
cerative colitis (p < 0.01). However, this increase was
found in only 33% of the patients with inactive
Crohn's disease, compared with 67% and 78% of
those with active Crohn's disease and ulcerative colitis,
respectively, and it appeared to be correlated to the
grade of the disease (fig. 2). Moreover, an increase of
15% in the monomeric IgA/total ratio was found in
patients with inflammatory bowel disease, relative to
the control group.
None of the studied laboratory quantities correlated
with the exact location of the disease.
Discussion
Our findings confirm the value of the intestinal clear-
ance of oci-antiproteinase for screening for intestinal
protein loss syndrome with good specificity and and
sensitivity (22). However, this quantity alone appears
to be insufficient for monitoring the course of inflam-
matory bowel disease, since no statistical difference
in the intestinal clearance of arantiproteinase was
found between patients with active and inactive
Crohn's disease. These data are in agreement with
those of Mizon et al. who demonstrated that oci-
antiproteinase was excreted in faeces in three different
molecular forms. One deglycosylated component of
Mr 38000, which can be underestimated in radial
immunodiffusion, is recovered in normal faecal ex-
tract and in some patients with inactive Crohn's dis-
ease, while two other components of MT 45 000 and
Mr 51 000 respectively, are found in patients with
active Crohn's disease (23).
Although O'Mahony et al. detected only very small
amounts of immunoglobulins in semi-liquid faecal
specimens from gut lavage (24), we found a significant
increase in the intestinal clearance of monomeric IgA
and IgG in most of our patients with active inflam-
matory bowel disease, correlated with the grade of
disease activity. This discrepancy was related to the
non-iatrogenic nature of our specimens and to the
relative resistance of monomeric IgA to intestinal
proteases. The protease susceptibility and faecal oc-
currence of IgG are poorly documented, but these
aspects are now under investigation in our laboratory.
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Since far greater increases in intestinal clearances of
monomeric IgA and IgG were found in most of the
patients with active Crohn's disease than in those with
inactive Crohrfs disease, these quantities appear to
reflect increased intestinal permeability. It therefore
seemed to be of interest to determine both the intes-
tinal clearance of monomeric IgA and IgG and that
of arantiproteinase, in order to monitor the degree
of intestinal bowel inflammation.
Moreover, this study supports previous immunohis-
tochemical findings showing that the number of IgA-
producing cells per mucosal tissue unit (gut lengh
unit) is increased according to the degree of inflam-
mation (12). In spite of the described reduction in J
chain expression during inflammatory bowel disease,
polymeric IgA production is sufficiently maintained
to afford an enhanced response of secretory IgA (25).
This increase in faecal polymeric IgA output, espe-
cially in patients with active Crohn's disease or ulcer-
ative colitis, confirmed that the activation of the mu-
cosal lymphoid system during inflammatory bowel
disease was proportional to the grade of the disease.
In addition, our results provide information on the in
vivo activation of the mucosal immune system during
inflammatory bowel disease. Although the pathogenic
mechanisms or antigens leading to these abnormalities
remain to be identified, the determination of the daily
faecal output of polymeric IgA may be of value for
assessing intestinal immunity during inflammatory
bowel disease, and the grade of the disease.
Conclusion
Our study, performed on an homogeneous population
of patients with inflammatory bowel disease assesses
the value of studying faecal constituents. It reveals
large differences between controls and inflammatory
bowel disease patients in terms of intestinal clearance
of arantiproteinase, IgG and monomeric IgA, as well
as faecal polymeric IgA output. However, because of
the large overlap between the results obtained in active
and inactive Crohn's disease, particulary for the two
Ig clearances, none fo the studied constituents can be
considered as a marker of inflammatory bowel disease
activity. In contrast, the combined study of the intes-
tinal clearance of arantiproteinase, monomeric IgA
and IgG, together with daily faecal output of poly-
meric IgA may provide a useful non-invasive tool for
assessing inflammatory bowel disease activity and
monitoring therapeutic efficacy.
To confirm the value of these measurements during
intestinal disease, we are now extending our investi-
gations to other kinds of inflammatory or exsudative
bowel disease, especially in HIV patients with and
without opportunistic digestive infections.
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